Hypertension: The framingham risk score is valuable in Europeans

Nature Reviews Nephrology

Volumn 6, Issue 1, 2010, Pages 14-15

  Ruilope, Luis M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; PLACEBO;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; EUROPE; FRAMINGHAM SCORE; HUMAN; HYPERTENSION; INSTRUMENT VALIDATION; LIFESTYLE MODIFICATION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SHORT SURVEY; UNITED STATES; CAUCASIAN; INCIDENCE; NOTE; RENOVASCULAR HYPERTENSION; REPRODUCIBILITY; RISK FACTOR; STATISTICS; UNITED KINGDOM;

EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; HYPERTENSION, RENAL; INCIDENCE; LONDON; REPRODUCIBILITY OF RESULTS; RISK FACTORS; UNITED STATES;

EID: 74849133095     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.205     Document Type: Short Survey

References (9)

1. ezzati, M., Lopez, A. D., Rodgers, A., vander Hoorn, s. & Murray, C. J. selected major risk factors and global and regional burden of disease. Lancet 360, 1347-1360 (2002).
2. Lawes, C. M., vander Hoorn, s. & Rodgers, A. Global burden of blood-pressure-related disease, 2001. Lancet 371, 1513-1518 (2008).
3. vasan, R. s., Larson, M. G., Leip, e. P., Kannel, w. B. & Levy, D. Assessment of frequency of progression to hypertension in nonhypertensive participants in the Framingham Heart study: a cohort study. Lancet 358, 1682-1686 (2001).
4. Chobanian, A. v. et al. seventh report of the Joint national Committee on Prevention, Detection, evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003).
5. Parikh, n. i. et al. A risk score for predicting near-term incidence of hypertension: the Framingham Heart study. Ann. Intern. Med. 148, 102-110 (2008).
6. Kivimäki, M. et al. validating the Framingham Hypertension Risk score: results from the whitehall ii study. Hypertension 54, 496-501 (2009).
7. Ruilope, L. et al. The kidney and cardiovascular risk--implications for management: a consensus statement from the european society of Hypertension. Blood Press. 16, 72-79 (2007).
8. He, J., whelton, P. K., Appel, L. J., Charleston, J. & Klag, M. J. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 35, 544-549 (2000).
9. Julius, s. et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med. 354, 1685-1697 (2006).